Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial

<p>Treatments for high-risk essential thrombocythemia (ET) address thrombocytosis, disease-related symptoms, as well as risks of thrombosis, hemorrhage, transformation to myelofibrosis and leukemia. Patients resistant/intolerant to hydroxycarbamide (HC) have a poor outlook. MAJIC (ISRCTN619257...

Full description

Bibliographic Details
Main Authors:	Harrison, C, Mead, A, Panchal, A, Fox, S, Yap, C, Gbandi, E, Houlton, A, Alimam, S, Ewing, J, Wood, M, Chen, F, Coppell, J, Panoskaltsis, N, Knapper, S, Ali, S, Hamblin, A, Scherber, R, Dueck, A, Cross, N, Mesa, R, McMullin, M
Format:	Journal article
Published:	American Society of Hematology 2017

Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial

Similar Items